Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + SBRT in Neoadjuvant Treatment for Stage IIA-IIIB NSCLC
NCT06293690Phase 2Active, not recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Apr 2024
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Started Apr 2024; status: active, not recruiting.
02
Drugs
toripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06293690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06293690.